

# HIV and Hepatitis Prevention Program Snapshot


## Program Supported HCV Screening: 2022

The HIV and Hepatitis Prevention Program partners with multiple stakeholders to support the strategic implementation of hepatitis C (HCV) testing services across Iowa.

In 2022, **10,636 rapid and conventional HCV tests** were administered in partnership with 64 agencies across five major settings (an increase of 42.9% from 2021):

- 12 Integrated Testing Services Agencies** providing clinical and prioritized outreach testing that are funded by Iowa HHS to support the implementation of these activities. Each site provides services in a geographic region and dedicates a minimum of 1.0 full-time employee or equivalent to the project;
- 13 Federally Qualified Health Centers** working to implement routine screening into primary care encounters in partnership with the Iowa Primary Care Association;
- 14 Substance Use Treatment** locations integrating HCV screening into medically assisted treatment programs for clients with opioid use disorder, including many clients who have a history of injection drug use;
- 22 Community-based Screening Services** projects working with Iowa HHS and the Family Planning Council of Iowa to provide HCV screening to qualified individuals (PWID) as part of safety-net STI screening services; and
- 3 Community-based Pharmacies** providing free rapid testing in areas that have been prioritized as vulnerable to HIV and HCV outbreaks related to injection drug use in partnership with the Iowa Pharmacy Association.

**Prevention Program Total HCV Testing and Positivity 2022**




*\*Data are not de-duplicated. Numbers represent testing instances and not unique individuals.*

Across all projects, the program reported a 2.33% total positivity rate in 2022, down from 3.06% in 2021.

Substance use treatment settings (delivering medically assisted treatment for opioid use disorders) had the highest positivity rate of any project, reported at 11.30%. This can be attributed to the prevalence of HCV transmission among people who use injection drugs (PWID) and the increased likelihood that PWID will be encountered in settings that provide treatment options for substance use disorders.

**Prevention Program HCV Testing Services Map 2022**



Indicators reflect services located within the associated county.